Eugia US LLC described the Skyline program as a two-part induction and maintenance platform trial for moderately-to-severely active UC patients consisting of three investigational antibodies: SPY001, SPY002, and SPY003.
Published
Signal category
Research & Knowledge
Quote
“The Skyline program is a two-part induction and maintenance platform trial for patients with moderately-to-severely active UC that consists of three investigational antibodies: SPY001, an anti-α4β7 antibody, SPY002, an anti-TL1A antibody and SPY003.”
— Donald DeWitt|Eugia US LLC team
Company
Eugia US LLC
Experience the Eugia Difference
- Industry
- Pharmaceutical Manufacturing
- Location
- Hightstown, US
- Company size
- 51 employees
Eugia is an independent specialty pharmaceutical company focused on delivering generic sterile injectables, oncology, hormones, and ophthalmic medicines. Our best-in-class, dedicated manufacturing and R&D capabilities are poised to meet today’s customer needs, and we are committed to providing our customers and partners with high-quality specialty medicines. Our name embodies who we aspire to be as a company – EU meaning “good” and hyGIA being the goddess of good health – together reflecting our focus on delivering products that are foundational to ensuring good health for millions of people around the world. For more information, visit EugiaUS.com